Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
我們正在追蹤 Samsung Biologics 的市場擴張
過去 90 日內有 8 個訊號。
Samsung Biologics 的國際擴張與競爭對手的比較
Samsung Biologics你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Samsung Biologics你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
The delivery of safe, high-quality medicines demands a culture where precision and compliance are deeply ingrained at every level. Dr Diane Black, EVP and Chief Quality Officer at Samsung Biologics, shares how our quality approach is put into practice through continuous process improvement. Our quality teams maintain a consistent presence on the manufacturing floor, providing real-time oversight and hands-on support throughout production. This close alignment strengthens process control, keeps p ...
已結束受中東緊張局勢影響,韓國綜合指數收於6475.63點近乎持平,而科斯達克指數飆升2.51%至1203.84點,自2000年以來首次突破1200點。
韓國綜合股價指數上漲2.25%至8228.70點,受半導體股推動,SK海力士飆升9.31%,三星電子上漲2.68%,而KOSDAQ下跌3.36%,市場呈現兩極分化。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Samsung Biologics 業務、市場及增長訊號的快速解答。
